secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2022-05-04T23:59:59+00:00
Accession:  0001396814-22-000031
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira Q1 rev $158M (+33% YoY), net income $6.8M, appoints COO
--------------------------------------------------------------

- Q1 revenue $158.0M (+33% YoY); EXPAREL $129.2M, ZILRETTA $23.6M (acquired Nov 2021).
- GAAP net income $6.8M ($0.15/sh); non-GAAP net income $29.9M ($0.67 basic).
- Adjusted EBITDA $53.8M ($1.16/diluted sh) vs $36.2M in Q1 2021.
- Daryl Gaugler appointed COO effective May 4, 2022; was SVP Commercial Ops.
- No revenue guidance due to COVID uncertainty; reiterates FY2022 opex guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681422000031/0001396814-22-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681422000031/pcrx-20220504.htm
  HTML page:      https://secwatch.observer/filing/0001396814-22-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer